Predictive Values of NLR, PLR and MPV for Pre-Eclampsia in Pregnancy: A Retrospective Cross-Sectional Study in a Teaching Hospital, Ghana

Kofi Mensah [a,b#]**, Charles Nkansah** [a,b++]*****, Samuel K. Appiah** [a,b†]**, Juliana Barnie** [c]**,
Doris T. Timbilla** [c]**, Samira Daud** [a‡]**, Dorcas Serwaa** [d^]**, Felix Osei-Boakye** [e##]**,
Charles A. Derigubah** [f]**, Simon B. Bani** [c] **and Gabriel Abbam** [a]

[a] *Department of Haematology, School of Allied Health Sciences, University for Development Studies, Tamale, Ghana.*
[b] *Department of Medical Laboratory Sciences, Faculty of Health Science and Technology, Ebonyi State University, Abakaliki, Nigeria.*
[c] *Department of Biomedical Laboratory Science, School of Allied Health Sciences, University for Development Studies, Tamale, Ghana.*
[d] *Department of Obstetrics and Gynecology, C4C Homeopathic Medical College, Greater Accra, Ghana.*
[e] *Department of Medical Laboratory Technology, Faculty of Applied Science and Technology, Sunyani Technical University, Sunyani, Ghana.*
[f] *Department of Medical Laboratory Technology, School of Applied Science and Arts, Bolgatanga Technical University, Bolgatanga, Ghana.*

Authors' contributions

This work was carried out in collaboration among all authors. Authors KM, CN, SKA, SBB, JB and DTT conceived and designed the study. Authors KM, CN, SKA, SBB, JB, DTT, FOB, SD, GA, CAD and DS wrote the protocol and the first draft of the manuscript. Authors JB and DTT participated in the data collection. Authors CN, JB, DTT, KM, SKA and FOB analysed and interpreted the data. Authors CN, KM, JB, DTT, and SBB managed the literature searches. Authors KM, CN, SKA, SBB, JB, DTT, FO-B, SD, GA, CAD and DS drafted the manuscript. All authors read and approved the final manuscript.

Article Information

Original Research Article

_____

[##] *ORCID ID: 0000-0001-5126-7424*
[^] *ORCID ID: 0000-0001-8583-4415*
[‡] *ORCID ID: 0000-0003-0133-1760*
[†] *ORCID ID: 0000-0002-9817-7212*
[#] *ORCID ID: 0000-0002-2238-2797*
[++] *ORCID ID: 0000-0001-6986-9976*
Corresponding author: E-mail: cnkansah86@yahoo.com, cnkansah@uds.edu.gh;

ABSTRACT

Aim: To assess the predictive values of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and mean platelet volume (MPV) for pre-eclampsia in pregnancy.

Study Design: Retrospective cross-sectional study.

Place and Duration of Study: Obstetrics and Gynecology unit of Tamale Teaching Hospital, Tamale, Ghana from 1st January, 2021 to 31st December, 2021.

Methodology: The study recruited 161 pregnant women (79 pre-eclamptic pregnant women and 82 apparently healthy pregnant women as controls). Full blood count parameters were assessed using fully automated haematology analyzer. Neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio were calculated. Data analysis was done with SPSS version 22.0 and $P<0.05$ was considered statistically significant.

Results: Pregnant women with PE had lower parity ($P< .001$) and gestational ages ($P< .001$) than their counterparts without PE. Haemoglobin ($P= .007$), red blood cells ($P= .003$), haematocrit ($P= .01$), absolute monocyte ($P= .001$) and MPV ($P= .02$) were significantly higher in the PE group compared to the controls. Also, pregnant women with PE had relatively higher MPV compared with the apparently healthy pregnant women without pre-eclampsia ($P= .02$), but NLR and PLR were not different between the two groups. Again, MPV significantly predicted PE (AUC: 0.609, $P< .02$) in pregnancy than NLR and PLR.

Conclusion: Lower parity and gestational ages are significantly associated with pre-eclampsia. Hb, RBC, HCT, absolute monocyte count and MPV were higher in pre-eclamptic pregnant women. MPV is a better marker for predicting asymptomatic PE in pregnancy. NLR and PLR did not significantly predict PE in pregnancy.

1. INTRODUCTION

Pre-eclampsia (PE) is a multi-organ condition that arises after 20 weeks' gestation and is characterized by high blood pressure (BP >140/90 mmHg) and proteinuria. It is amongst the most prevalent pregnancy problems, involving 3–5% of all expectant mothers and common cause of maternal and perinatal mortality [1,2]. PE accounts for 12% of all maternal deaths worldwide,[1] but its contribution to feto-maternal morbidity and mortality is worsened in developing countries, with 10% rate of complication compared to the global complication rate of 2–8% [3,4]. The prevalence of PE differs greatly globally, with its occurrence estimated to be seven times higher in developing countries, constituting 2.8% of live births as compared to 0.4% in developed countries [5].

Owiredu et al., [6] confirmed that women who are obese, having gestational diabetes, multifetal pregnancy, a family record of PE, primigravida, and pregnancy at an advanced age of 40 and above or a young age of 18 and below are at higher risk of developing pre-eclampsia. Also, pre-existing medical disorders such as women with persistent high blood pressure, are at a higher risk factors of developing PE in pregnancy [7,6].

Although the etiology and pathogenesis of PE presently remain unclear [8], pre - eclampsia may be related to a defective placental growth due to improper spiral artery remodeling and poor trophoblast invasion/differentiation. This results in a poor perfusion leading to ischaemia, triggering the production of cytokines like soluble fms-like tyrosine kinase-1 (sFlt-1) and vascular endothelial growth factor (VEGF), which cause systemic endothelial malfunction as well as the disease's systemic consequences [9,10]. Approximately 5-7% PE related pregnancy complications usually results from a diffused endothelial cell dysfunction, and this is associated with systemic inflammatory response in the mother [11]. The systemic changes caused by PE may affect hematological parameters such as red blood cell, platelets and leucocyte parameters during pregnancy. Recent studies have proposed the use of systemic inflammatory markers such as Neutrophil to Lymphocyte Ratio (NPR), Platelet to Lymphocyte Ratio (PLR), Red Cell Distribution Width (RDW), Mean Platelet Volume (MPV) and Plateletcrit (PCT) to predict and/or diagnose various diseases including ischaemic heart disease, and systemic inflammatory diseases such as pre-eclampsia [11,12].

Few studies have investigated the nature of the hematological parameters in patients with PE, and have reported conflicting findings [12-16]. Also, almost all of the studies done so far singularly assessed individual ratio at a point in time, and did not consider combining all the ratios from the hematological parameters to predict PE in pregnancy. Again, to the best of our knowledge, no study has ever assessed the predictive and/or diagnostic values of the above hematological markers for PE in the Northern part of Ghana.

Therefore, this study was designed to assess the predictive values of NLR, PLR and MPV for pre-eclampsia in pregnancy in Tamale.

2. MATERIALS AND METHODS

2.1 Study Site and Study Design

This retrospective cross-sectional study was carried out at the Pre- and Post-Natal Care Units of the Obstetrics and Gynecology Department of the Tamale Teaching Hospital (TTH) from 1st January, 2021 to 31st December, 2021. TTH is the main referral hospital to the inhabitants of the Northern, the Upper East, the Upper West, Savannah, and North East Regions of Ghana. The essential units in the Obstetrics and Gynecology Department of the hospital include the Pre- and Post-Natal units where antenatal, delivery, and post-natal care are given to women during and after pregnancy. Tamale, being the capital of the Northern region of Ghana has a total estimated land size of 646.90180sqkm, with population of about 233,252. Geographically, Tamale Metropolis lies between latitude 9º16 and 9º34 North and longitudes 0º 36 and 0º 57 West [17].

2.2 Study Population and Data Collection

A total of 161 pregnant women attending TTH were selected for the study. Pregnant women diagnosed of pre-eclampsia at gestational age of 20 weeks and above were included in the study as cases. Pregnant women without PE and of gestational ages equal to or above 20 weeks who visited the Pre- or Post-Natal Units of the Tamale Teaching Hospital were selected as controls. Data on the participants were collected from the hospital's records. The gestational ages were determined and recorded in the hospital's register after the pregnant women had gone through extensive physical examinations and ultrasound scan by specialists. Pregnant women

with history of chronic hypertension, renal disorders, haematological disorders prior to pregnancy and other known abnormalities were excluded. Also, pregnant women who were on any medication that may influence the results of complete blood count were excluded from the study. The study again excluded participants whose data were not complete from the hospital's register.

2.3 Diagnostic Criteria

Diagnosis of Pre-eclampsia was based on American College of Obstetricians and Gynecologists (ACOG) criteria which is described as new-onset high blood pressure (systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg) and new-onset proteinuria in a formerly normotensive woman after 20 weeks of pregnancy. It also includes the presence of proteinuria which is described as a urine protein/creatinine ratio of 0.3 mg/dL or 300 mg of protein in 24 hours; however, in its absence, the urine dipstick should be utilized [18].

2.4 Blood Pressure Measurements (Using Krotkoff 1 and 5)

Blood pressure was measured by trained personnel using a mercury sphygmomanometer and a stethoscope. Measurements were taken from the left upper arm after participants sat >5 min in harmony with the recommendations of the American Heart Association. Duplicate measurements were taken with a 5-minute rest interval between measurements by a different professional and the average value was recorded in mmHg. Hypertension was established when the systolic blood pressure (SBP) as >140 mm Hg and diastolic blood pressure (DBP) >90 mm Hg [19].

2.5 Laboratory Investigations

About 5 ml of whole blood was collected from each participant and dispensed into Ethylenediamine tetraacetic acid (EDTA) tube and mixed gently. Complete blood count was performed on participant's blood using URIT 5250 5-parts Hematology analyzer, China, to estimate RBC count, Hb concentration, mean cell volume, mean cell Hb, mean cell Hb concentration and red cell distribution width at the Hematology Laboratory unit of TTH. Dipstick proteinuria using reagent strips from Yercon

Diagnostic Co. Ltd, P.R. of China, were also performed on fresh urine samples collected from the participants.

2.6 Data Analysis

The data obtained was captured with Microsoft Excel and analyzed using IBM Statistical Package for the Social Sciences (SPSS) version 23. The data were presented in tables and figures. Normality test for the distribution of the data was performed using Kolmogorov-Smirnov test. The numerical (non-parametric) data were presented as medians (25th-75th percentiles). Mann-Whitney U-Test was used to compare bivariate numerical data. ROC analysis was performed to determine the sensitivity, specificity and area under the curve (AUC) of the variables. Statistical significance was set at $p<0.05$.

3. RESULTS

3.1 Demographics and Obstetric Parameters of the Study Participants Stratified by the Presence or Absence of Pre-eclampsia

A total of 161 participants were involved in this study; comprising 79 (49%) pre-eclamptic pregnant women and 81(51%) healthy pregnant women without pre-eclampsia. There was no statistical difference between the median ages of the pre-eclamptic pregnant women and the controls [31 (26-34) vs 29 (24-33), *P*= .13]. The median parity and gestational ages were significantly lower in the pre-eclamptic pregnant women compared with the apparently healthy pregnant women without PE: [Parity: 1 (0-3) vs 2 (0-3), *P*< .001; Gestational age: 35 (31-38) vs 37 (34-39), *P*< .001], as shown in Table 1.

3.2 Complete Blood Count Parameters of the Study Participants Stratified by the Presence or Absence of Pre-eclampsia

Table 2 shows the results of complete blood count parameters between the two groups. Hemoglobin (Hb), Red Blood Cell Count (RBC), Hematocrit (HCT), Absolute Monocytes and Mean Platelet Volume (MPV) were all significantly higher in pre-eclamptic women compared to pregnant women without pre-eclampsia [Hb in g/dl: 10.70 (9.60-11.90) vs 10.10 (8.88-11.10), *P*=.01; RBC: 4.13 (3.64-4.53) vs 3.83 (3.47-4.18)×10^{12}/L, *P*=.003; HCT: 32.70 (29.30-36.80) vs 30.90 (27.57-33.92) %, *P*=.01;

Abs. Monocyte: 0.52 (0.34-0.68) vs 0.37 (0.23-0.54) ×10^9/L, *P*=0.001; MPV: 7.10 (6.80-7.60) vs 6.90 (6.47-7.32) fL, *P*=.02]. MCV, MCH, MCHC, TWBC, RDW, Platelet, PCT, PDW, Absolute neutrophil, lymphocyte, eosinophil and basophil did not differ between pregnant women with PE and those without the condition (Table 2).

3.3 Comparison of NLR, PLR and MPV between Pregnant Women with Pre-eclampsia and Those without Pre-eclampsia

Fig. 1 shows the median NLA (1A), PLR (1B) and MPV (1C) of pregnant women with pre-eclampsia compared with the healthy pregnant women without pre-eclampsia. The median NLR among the pre-eclamptic group was higher, 2.24 (1.29-3.35) compared with the healthy pregnant women without pre-eclampsia, 2.18 (1.31-3.13), but this was not significant statistically (*P*= .71).

When the median PLR of pregnant women with PE was compared with the median PLR of the pregnant women without PE, no significant difference was observed: [92.28 (54.63-130.55) vs 95.32 (53.73-136.29), *P*= .80]. However, the MPV among the pregnant women with pre-eclampsia was relatively higher [7.10 (6.80-7.60)] compared with the apparently healthy pregnant women without pre-eclampsia [6.90 (6.47-7.32)] and this was statistically significant (*P*= .02) as shown in Fig. 1.

3.4 Predictive Values of NLR, PLR and MPV for Pre-eclampsia in Pregnancy

Table 3 shows a multivariate analysis used in determining the diagnostic values of NLR, PLR and MPV in pregnant women with pre-eclampsia. With the optimum cut-off points for NLR, PLR and MPV at 3.08, 126.80 and 10.40 respectively, the sensitivity and specificity of the markers were: NLR (Sensitivity:55.3%, Specificity: 53.5%, 95%CI: 0.4333-0.612, *P*= .62), PLR: (Sensitivity:50.0%, Specificity: 51.3%, 95%CI: 0.396-0.575, *P*= .75), and MPV: (Sensitivity: 44.8%, Specificity: 40%, 95%CI: 0.522-0.696, *P*= .02). MPV showed as the better predictive marker for pre-eclampsia in pregnancy (AUC=0.609, *P*= .02) (Table 3).

4. DISCUSSION

Pre-eclampsia (PE) is one of the significant contributors of feto-maternal morbidity and mortality globally, but the situation is pronounced especially in developing countries. Early

diagnosis coupled with appropriate management may prevent the associated complications on both the mother and the fetus or newborn [20]. The diagnosis of PE is limited to hypertension (BP >140/90 mmHg) and proteinuria at 20 or more weeks of gestation [18]. This study aimed to assess the diagnostic values of full blood count parameters: NLR, PLR and MPV for the prediction and/or diagnosis of PE.

The significant association between lower parity and pre-eclampsia observed in this study is in consonance with an earlier retrospective case-control study [21]. Pre-eclampsia is known to complicate nulliparous pregnancies in 25-30% of cases, and affects more primigravida women than multigravida women, therefore making the first pregnancy a significant risk factor [22]. Consequently, pre-eclampsia reduces the blood flow to the placenta, resulting in poor intrauterine growth and abnormally early birth [23]. Lower gestational age was identified to be significantly associated with pre-eclampsia in the current study, and this agrees with a retrospective study by Mannaerts et al., [24].

Again, advanced maternal age has been linked with the development of PE. A similar study by Owiredu et al., [7] in Ghana indicated that the probability of getting PE rose considerably with maternal age, from twice among women with ages 35-39 to almost thrice among women with ages between 40-44 when compared to women between the ages of 25-29. Women below 25 years were not at an increased risk of PE when compared to women between the ages of 25 and 29. However, the current study did not find any significant difference in the maternal ages of pregnant women with PE and those without PE. This finding from the present study is similar to the findings from the Çintesun et al., study [21] which did not detect any association between maternal age and pre-eclampsia. This variation may be related to the differences in geographical settings of the studies.

The pregnant women with pre-eclampsia in this study had significantly higher Hematocrit (HCT), Hemoglobin (Hb), Red blood cells (RBC) and absolute monocytes compared with their counterparts without PE. The observed significantly increased HCT, Hb and RBC in the pregnant women with pre-eclampsia are comparable to a previous finding [25]. The Pritchard et al., [25] study suggests that endothelial dysfunction, which is a common occurrence in PE, causes widespread leakage of fluid into the interstitial tissues, resulting in hemoconcentration. Again, regardless of the usual rise in intravascular volume during normal pregnancy, pre-eclamptic pregnant women experience serum protein loss and a rise in the permeability of capillary endothelium leading to a drop in the intravascular volume and increased tissue oedema [26]. Elevated HCT and Hb are thus seen as better indicators of PE, and a decrease in recurring hematocrit levels could improve clinical outcome [27]. The Walker [27] study appreciates the unique roles of the liver, lung and brain, especially in fluid distribution. Therefore, a malfunction in essential organs including the heart, liver, kidneys, etc which occur in PE, contribute to hemoconcentration leading to decreased plasma volume and increased RBC, HCT and Hb. However, contrary to our study, a retrospective study in 2016 found significantly lower Hb in PE compared to pregnant women without PE [28].

Also, the current study revealed a significantly higher MPV in the pregnant women with PE compared to the control group of healthy pregnant women. Järemo et al., [29] also demonstrated a higher MPV (9.8±0.7 fL) in women with PE than in pregnant women without PE (8.8±1.2 fL). Another study reported MPV increase in PE when comparing severe PE and normotensive pregnant women (9.6±1.1 vs 9.1±0.9 fL) [30]. Similarly, a recent retrospective study reported significantly higher MPV (8.64 fL ± 1.17) in the PE group compared to the control group with a mean MPV (8.06±0.87 fL, *p*=0.006) [24]. Findings from a longitudinal study by Dundar et al., [31] demonstrated that during normal pregnancy, MPV levels rise, but this rise is more prominent in women with pre-eclampsia. Again, Yücel and Ustun reported a significantly higher MPV value in the severe PE group, 9.92fL (6.84-16.61 fL) compared to control group of 8.60fL (5.18-14.32) [11]. Thrombocytes activation and aggregation results in increased consumption of platelets and this is a common occurrence in PE [32]. This depletion of platelets in the peripheral blood triggers the bone marrow's compensatory mechanisms to compensate for the loss by synthesizing several new platelets. As the rise in platelet aggregation is counterbalanced by an increase in platelet synthesis, platelets of varying sizes are released into the circulation as compensatory mechanism to prevent bleeding and this causes the MPV to appear increased, especially in pregnancy [33]. Gladwin and Martin's study [34], showed that low oxygen levels in circulation stimulates both the

synthesis and breakdown of platelets, resulting in an increase in MPV levels. MPV is indirectly proportional to platelet count in physiological conditions, which is associated with maintaining haemostasis and maintaining continuous platelet mass [35]. On the contrary, findings from the current study disagree with some previous studies. In the study by Çintesun et al., [21] MPV value was shown to be significantly higher in the control group compared to both mild and severe PE, nevertheless, no significant variation was discovered in mild and severe PE groups. Again, the aforementioned study presented no significant difference in platelet count and MPV values between PE group and control group. Other studies reported lower platelets and higher MPV in the PE group than in the control group [24-30]. The inconsistencies in the findings could be attributed to: pre-analytical factors such as; the expertise of the phlebotomist, phlebotomy method (with or without stasis), the correct filling of the tube with blood, the proper mixing of sample and the anticoagulant utilized for blood collection; centrifugation of the blood put into citrate anticoagulant could result in platelet activation, causing the presence of more active large platelets; difference in MPV value is reduced in platelet-rich-plasma as measured against whole blood. The pre-analytic errors may trigger initial platelet activation and affect MPV values.

Table 1. Demographics and obstetric parameters of the study participants stratified by the presence or absence of pre-eclampsia

Variables	Pregnant women with Pre-eclampsia (n=79)	Pregnant women without Pre-eclampsia (n=82)	*P*-value
Age (years)	31 (26-34)	29 (24-33)	.13
Parity	1 (0-3)	2 (0-3)	< .001*
Gestational age (weeks)	35 (31-38)	37 (34-39)	< .001*

Data are presented in medians (25th-75th percentiles). Mann-Whitney U test was used to generate the data and statistical significance was set at P<.05. (*) represent statistically significant parameters

Table 2. Complete blood count parameters of the study participants stratified by the presence or absence of pre-eclampsia

Complete blood count parameters	Pregnant women with pre-eclampsia (n=79)	Pregnant women without pre-eclampsia (n=82)	*P*-value
Hb (g/dl)	10.70 (9.60-11.90)	10.10 (8.88-11.10)	.007*
RBC ($\times 10^{12}$/L)	4.13 (3.64-4.53)	3.83 (3.47-4.18)	.003*
HCT (%)	32.70 (29.30-36.80)	30.90 (27.57-33.92)	.01*
MCV (fL)	82.20 (75.50-86.80)	81.65 (76.8-85.4)	.81
MCH (pg)	27.00 (24.10-28.40)	26.05 (24.52-28.40)	.81
MCHC (g/dl)	32.80 (31.60-34.00)	32.20 (31.18-33.32)	.22
RDW-CV (%)	10.20 (9.30-11.50)	10.30 (9.27-11.30)	.95
TWBC ($\times 10^9$/L)	8.28 (6.70-10.38)	7.71 (5.84-10.67)	.37
Abs. Neut. ($\times 10^9$/L)	4.87 (3.67-6.67)	4.47 (2.97-6.49)	.48
Abs. Lymph. ($\times 10^9$/L)	2.39 (1.60-3.20)	2.05 (1.61-3.20)	.67
Abs. Mono. ($\times 10^9$/L)	0.52 (0.34-0.68)	0.37 (0.23-0.54)	.001*
Abs. Eos. ($\times 10^9$/L)	0.09 (0.05-0.14)	0.08 (0.04-0.11)	.28
Abs. Baso ($\times 10^9$/L)	0.01 (0.01-0.02)	0.01 (0.01-0.02	.12
Platelet ($\times 10^9$/L)	220.00 (154.00-277.00)	202.50 (161.8-258.3)	.90
MPV (fL)	7.10 (6.80-7.60)	6.90 (6.47-7.32)	.02*
PCT (%)	0.15 (0.11-0.19)	0.14 (0.11-0.18)	.51
PDW (%)	8.60 (7.90-9.70)	8.30 (7.60-9.47)	.14

Hb= Hemoglobin; RBC= Red Blood Cell; HCT= Hematocrit; MCV= Mean Cell Volume; MCH= Mean Cell Hemoglobin; MCHC= Mean Cell Hemoglobin Concentration; RDW-CV= Red Cell Distribution Width- Coefficient of Variation; g/dl= grams per deciliter; fL= Femtolitre; pg=Pico gram; L=Litre. Data are presented in medians (25th-75th) Percentiles, Data were compared using Mann- Whitney U test and statistical significance was set at P<.05. (*) represent statistically significant parameters

**Fig. 1. Comparison of [a] NLR, [b] PLR, and [c] MPV between Pregnant Women with
Pre-eclampsia and those without Pre-eclampsia**
Statistical significance was set at P<.05

Table 3. Predictive values of NLR, PLR and MPV for pre-eclampsia in pregnancy

Markers	Sensitivity	Specificity	Cut-off value	AUC	95% CI	*P*-value
NLR	55.3	53.5	3.08	0.523	0.433-0.612	.62
PLR	50.0	51.3	126.8	0.486	0.396-0.575	.75
MPV	44.8	40.0	10.4	0.609	0.522-0.696	.02*

NLR= Neutrophil to Lymphocyte Ratio; PLR= Platelet to Lymphocyte Ratio; MPV= Mean Platelet volume. 95% CI-95% Confidence Interval, AUC= Area under Curve

This study did not find any significant difference in NLR values between PE group and the control group. This finding is in agreement with previous studies [11,16,21]. In contrast to findings from this study, a previous study comprising 107 pregnant women found NLR values to be significantly increased in pre-eclamptic women than in the control group [36]. Similarly, a retrospective study involving pregnant women reported a significantly higher NLR values in the PE group than in the control group without PE [24]. Also, the present study did not observe any significant difference in the PLR values between the preeclamptic women and the control group, and this finding is consistent with previous studies [37,38]. Surprisingly, the Kirbas et al., [38] study involved pregnant women in their first trimester, and stratified the PE subjects into severe and mild groups, where a significantly higher PLR was recorded among the former group. The discrepancies in their findings were attributed to the period and state of the pregnant women; as the evaluation was done in early months of pregnancy.

Furthermore, MPV was observed to be a better predictor of pre-eclampsia compared to NLR and PLR in this study. This finding is similar to a study by Dundar et al., [31] where a sensitivity and specificity of 78% and 86%, respectively, for detecting pre-eclampsia using MPV at 24-28 weeks gestation were recorded. Another study by Yücel and Ustun also recorded similar finding in 2017 [11]. The variation in the sensitivity and specificity may be related to the differences in cut-off values employed as well as the sample sizes used. The current study used MPV cut-off point of 10.4fL whilst the Dundar et al., [31] and Yücel and Ustun [11] used cut-off points of 10.5fL and 8.04fL, respectively. The present study did not identify NLR and PLR as better inflammatory markers for predicting pre-eclampsia in pregnancy.

The study was limited by our inability to assess other inflammatory markers. Also, the ratios should be used in conjunction with other known diagnostic tests for PE.

5. CONCLUSION

Lower parity and gestational ages are significantly associated with pre-eclampsia. Pregnant women with pre-eclampsia had significantly higher Hb, RBC, HCT, absolute monocytes and MPV. Also, MPV was observed to be a better predictive and/or diagnostic marker for pre-eclampsia. It is recommended that periodic assessment of haematological parameters, including MPV be done for pregnant women, and those with high levels be monitored closely for signs of pre-eclampsia.

CONSENT

It is not applicable.

ETHICAL APPROVAL

Ethical clearance for the study was obtained from the Department of Research and Development at Tamale Teaching Hospital (TTH/R&D/SR/164). Permission was also sought from the management of TTH.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Roberts J, Cooper DW. Pathogenesis and genetics of pre-eclampsia. The Lancet. 2001;357:53-56.
2. Witlin A, Sibai B. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet. Gynecol. 1998;92:883–889.

3. Vata PK, Chauhan NM, Nallathambi A, et al. Assessment of prevalence of preeclampsia from Dilla region of Ethiopia. BMC Res. Notes. 2015;8:1–6.

4. Nakimuli A, Chazara O, Byamugisha J, et al. Pregnancy, parturition and preeclampsia in women of African ancestry. Am. J. Obstet. Gynecol. 2014; 210:510–520.

5. WHO. The World health report: 2005: Make every mother and child count. (World Health Organization); 2005.

6. Owiredu W, Ahenkorah L, Turpin CA, et al. Putative risk factors of pregnancy-induced hypertension among Ghanaian pregnant women. J. Med. Biomed. Sci. 2012;1:62–76.

7. Obed SA, Patience A. Birth weight and ponderal index in pre-eclampsia: A comparative study. Ghana Med. J. 2006;40:8.

8. Hung TH, Skepper JN, Charnock-Jones DS, et al. Hypoxia-reoxygenation: A potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circ. Res. 2002;90:1274–1281.

9. McKeeman GC, Ardill JES, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am. J. Obstet. Gynecol. 2004;191:1240–1246.

10. Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: A systematic review. Obstet. Gynecol. 2007;109:168–180.

11. Yücel B, Ustun B. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, red cell distribution width and plateletcrit in preeclampsia. Pregnancy Hypertens. An Int. J. Women's Cardiovasc. Heal. 2017;7:29–32.

12. Vilchez G, Lagos M, Kumar K, et al. Is mean platelet volume a better biomarker in pre-eclampsia? J. Obstet. Gynaecol. Res. 2017;43:982–990.

13. Abor PA. Managing healthcare waste in Ghana: A comparative study of public and private hospitals. Int. J. Health Care Qual. Assur; 2013.

14. Han L, Liu X, Li H. Blood coagulation parameters and platelet indices: Changes in normal and preeclamptic pregnancies and predictive values for preeclampsia. PLoS One. 2014;9:e114488.

15. Kashanian M, Hajjaran M, Khatami E, et al. Evaluation of the value of the first and third trimester maternal mean platelet volume (MPV) for prediction of pre-eclampsia. Pregnancy Hypertens. An Int. J. Women's Cardiovasc. Heal. 2013;3:222–226.

16. Kurt RK, Aras Z, Silfeler D, et al. Relationship of red cell distribution width with the presence and severity of preeclampsia. Clin. Appl. Thromb. 2015;21:128–131.

17. Ghana Statistical Service. Tamale metropolis. District Analytical Report: Tamale Metropolis, Ghana; 2014.

18. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' task force on hypertension in pregnancy. Obstet. Gynecol. 2013;122:1122–1131.

19. Nkansah C, Addai-Mensah O, Mensah K, et al. Plasminogen activator inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana. PLoS ONE. 2021;16:e0250090.

20. Snydal S. Major changes in diagnosis and management of preeclampsia. J. Midwifery Womens. Health. 2014;59:596–605.

21. Çintesun E, Çintesun FNI, Ezveci H, et al. Systemic inflammatory response markers in preeclampsia. J. Lab. Physicians. 2018;10:316–319.

22. Serhal P, Craft I. Immune basis for pre-eclampsia evidence from oocyte recipients. Lancet (London, England). 1987;2:744.

23. Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in perinatology. Elsevier. 2009;33:130–137.

24. Mannaerts D, Heyvaert S, De Cordt C, et al. Are neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and/or mean platelet volume (MPV) clinically useful as predictive parameters for preeclampsia? J. Matern. Neonatal Med. 2019;32:1412–1419.

25. Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. Am. J. Obstet. Gynecol. 1984;148:951–963.

26. Chappell L, Bewley S. Pre-eclamptic toxaemia: The role of uterine artery Doppler. BJOG An Int. J. Obstet. Gynaecol. 1998;105:379–382.

27. Walker JJ. Pre-eclampsia. Lancet. 2000; 356:1260–1265.

28. Gezer C, Ekin A, Ertas IE, et al. High first-trimester neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are indicators for early diagnosis of preeclampsia. Ginekol. Pol. 2016;87:431–435.

29. Järemo P, Lindahl T, Lennmarken C, et al. The use of platelet density and volume measurements to estimate the severity of pre-eclampsia. Eur. J. Clin. Invest. 2000;30:1113–1118.

30. Freitas LG, Alpoim PN, Komatsuzaki F, et al. Preeclampsia: Are platelet count and indices useful for its prognostic? Hematology 2013;18:360–364.

31. Dundar O, Yoruk P, Tutuncu L, et al. Longitudinal study of platelet size changes in gestation and predictive power of elevated MPV in development of pre-eclampsia. Prenat. Diagnosis Publ. Affil. With Int. Soc. Prenat. Diagnosis 2008;28:1052–1056.

32. Piazze J, Gioia S, Maranghi L, et al. Mean platelet and red blood cell volume measurements to estimate the severity of hypertension in pregnancy. J. Perinat. Med. 2006;34:246–247. DOI 10.1515/JPM.2006.044

33. Stubbs TM, Lazarchick J, Van Dorsten JP, et al. Evidence of accelerated platelet production and consumption in nonthrombocytopenic preeclampsia. Am. J. Obstet. Gynecol. 1986;155:263–265.

34. Gladwin AM, Martin JF. The control of megakaryocyte ploidy and platelet production: Biology and pathology. Int. J. Cell Cloning. 1990;8:291–298.

35. Thompson CB, Jakubowski JA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood. 1988;72:1-8.

36. Serin S, Avcı F, Ercan O, et al. Is neutrophil/lymphocyte ratio a useful marker to predict the severity of pre-eclampsia? Pregnancy Hypertens. An Int. J. Women's Cardiovasc. Heal. 2016;6:22–25.

37. Yavuzcan A, Caglar M, Ustun Y, et al. Mean platelet volume, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in severe preeclampsia. Ginekol. Pol. 2014;85(3). DOI: 10.17772/gp/1713

38. Kirbas A, Ersoy AO, Daglar K, et al. Prediction of preeclampsia by first trimester combined test and simple complete blood count parameters. J. Clin. diagnostic Res. 2015;9:QC20.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/94376